SOUTH JORDAN, Utah, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today announced that management will participate in the 44th Annual J.P. Morgan Healthcare Conference, which is being held at The Westin St. Francis Hotel in San Francisco, California, January 12-15, 2026. To learn more, visit Healthcare Conference. Martha G. Aronson, President and Chief Executive Officer, and Raul Parra, Chief Financial Officer, will present a company ...

CASE DETAILS: According to the filed complaint, defendants made false statements and/or concealed that: In truth, the launch of the Company's new product, Inspire V, was a disaster because demand for Inspire V was poor, as providers had significant amounts of surplus inventory and were reluctant to transition to a new treatment. Moreover—and contrary to defendants' statements assuring investors that Inspire had taken all necessary steps to ensure a successful launch and, later, that the launch was in fact p ...

NEW YORK, Dec. 23, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Integer Holdings Corporation ("Integer Holdings Corporation" or the "Company") (NYSE: ITGR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Integer Holdings Corporation investors who were adversely affected by alleged securities fraud between July 25, 2024 and October 22, 2025. Follow the link below to get more information and be contacted by a member of our team: htt ...

Access the segment here THE WOODLANDS, TX, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it recently participated in a Virtual Investor CEO Connect segment. As part of the segment, Brad Hauser, CEO of Autonomix, outlined two key priorities shaping the Company’s trajectory: strengthening its platform through intellectual property protection and evalua ...

NEW YORK, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Integer Holdings Corporation (NYSE: ITGR) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Integer, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/integer-holdings- ...

NEW YORK, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Inspire, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/inspire-medical- ...

RA'ANANA, Israel, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today reaffirmed its previously announced binding purchase orders totaling $49.5 million and provided an update on execution timing, noting that payment activity has been structured to commence with the 2026 fiscal cycle, in alignment with immediate regulatory sequencing and phased deployment milestones.The Com ...

Revenues Relating to the Binding Purchase Orders Expected to be Received and Recognized in 2026RA'ANANA, Israel, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today reaffirmed its previously announced binding purchase orders totaling $49.5 million and provided an update on execution timing, noting that payment activity has been structured to commence with the 2026 fiscal c ...

第六批高值耗材集采概览 - 国家组织第六批高值医用耗材集中带量采购于12月22日发布文件，锁定药物涂层球囊和泌尿介入两大领域，覆盖12个细分品种，年度总需求量超过340万个（套），采购周期自执行日起至2028年12月31日 [4] - 申报企业需在2026年1月12日前确认供应产品，现场递交材料及信息公开于1月13日开展，由天津市医药采购中心负责具体实施 [4] 集采品种与需求量 - 药物涂层球囊类涵盖冠状动脉及外周血管（用于动静脉瘘透析通路、膝上、膝下部位）四个品种，年度总需求量达69万个 [9] - 冠状动脉药物涂层球囊需求最旺盛，年度需求量61.48万个，垠艺生物、乐普医疗、申淇医疗需求量位居前列，分别为11.33万个、9.71万个、8.69万个 [9] - 泌尿介入类涵盖输尿管介入导丝、介入鞘等8个品种，年度总需求量超过275万个（套） [9] - 输尿管介入导丝是最大单品，年度需求量达137.24万个，瑞邦医疗、库珀医疗、莱凯医疗占据需求前列 [9] 市场格局与国产替代 - 冠状动脉药物涂层球囊与用于膝上部位的外周血管药物涂层球囊，国内企业与跨国企业市场占比大致为80%和20% [9] - 用于动静脉瘘透析通路和膝下部位的外周血管药物涂层球囊，医疗机构年度需求量均为国内企业产品 [9] - 输尿管介入导丝市场，国内企业与跨国企业占比也大致为80%与20% [10] - 具备测量靶向部位生理压力功能的输尿管介入鞘和一次性输尿管软镜导管，医疗机构年度需求量均为国内企业产品，国产替代加速 [10] 最高有效申报价与定价逻辑 - 最高有效申报价制定基本延续征求意见稿思路，对未集采品种主要参考挂网均价的5折 [10][11] - 冠状动脉药物涂层球囊近两年带量采购中标价多为5555元，本次最高有效申报价为5600元 [11] - 不具备压力测量功能的一次性输尿管软镜挂网价约4000元，本次最高有效申报价为1860元，符合非集采挂网均价5折的核心逻辑 [11] - 各品种最高有效申报价及70%标准详见文件表格，例如肾造瘘套件最高有效申报价为1000元 [12][13] 集采规则优化与影响 - 本次集采首次引入“锚点价”概念，设置为同竞价单元入围企业“竞价比价价格算数平均价的65%”与“最低竞价比价价格”二者取高值，均价比例由流传意见稿的60%提升至65% [19] - 竞价比价价格不得超过同竞价单元“锚点价格”的1.5倍 [19] - 设置多重复活机制，未中选企业可通过下调报价再次争取中选资格，但按规则三中选的复活企业不具备剩余量分配资格 [20] - 医疗机构分配剩余量时，可选择排名前40%的中选企业（规则三中选除外）或填报过需求量的中选企业（规则三中选除外） [20] - 集采规则变革将加速行业重构，国产头部企业有望成为最大受益者，外资企业面临本土化转型压力，中小企业则将加速退出市场，行业集中度进一步提升 [22]

帕纳萨斯核心股票基金2025年第三季度表现 - 帕纳萨斯核心股票基金（投资者份额）在2025年第三季度净回报率为2.57%，同期标普500指数回报率为8.12%，基金表现落后于基准指数[1] - 年初至今，该基金回报率为9.89%，而标普500指数回报率为14.83%[1] - 第三季度市场上涨主要由对货币宽松的预期、强劲的消费者需求和稳健的企业盈利所推动的投资者乐观情绪驱动[1] 波士顿科学公司投资亮点 - 帕纳萨斯基金在第三季度减持了礼来公司和史赛克公司，并用所得资金新建了波士顿科学公司的头寸，将其视为一家拥有显著增长驱动力的创新型医疗器械制造商[3] - 波士顿科学公司的先发优势、稳健的临床数据以及与医生的深厚关系使其能够保持主导市场份额并超越竞争对手[3] - 公司额外的增长驱动力包括Watchman和Farapulse等产品，有助于其在渗透不足的市场中快速扩张[3] - 由首席执行官Mike Mahoney领导的管理层通过严格的研发和并购转型了公司，推动了有机销售增长和利润率扩张[3] - 凭借稳定的执行力、不断扩大的利润率以及全球需求顺风，波士顿科学公司有望实现持续增长[3] 波士顿科学公司财务与市场数据 - 波士顿科学公司2025年第三季度合并营收达到50.65亿美元，较2024年第三季度增长20.3%[4] - 截至2025年12月22日，公司股价报收于96.43美元，市值为1429.52亿美元[2] - 公司股票一个月回报率为-4.86%，过去52周回报率为5.89%[2] - 截至第三季度末，共有102只对冲基金投资组合持有波士顿科学公司股票，较前一季度的100只有所增加[4]